Skip to main content
Publications
Handels R, Herring WL , Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease . Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006
Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S , Li B, Esterberg E , Makari D, Candrilli SD , Goyal RK , Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer . Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719
Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S , Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma . Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289
van der Veer SN, Griffiths-Jones D, Parkes M, Druce KL , Amlani-Hatcher P, Armitage CJ, Bansback N, Bower P, Dowding D, Ellis B, Firth J, Gavan S, Mackey E, Sanders C, Sharp CA, Staniland K, Dixon WG, REMORA team. Remote monitoring of rheumatoid arthritis (REMORA): study protocol for a stepped wedge cluster randomized trial and process evaluation of an integrated symptom tracking intervention . Trials. 2024 Oct 15;25(1):683. doi: 10.1186/s13063-024-08497-9
Haug U, Morales DR, Ehrenstein V, Esen BO, Didelez V, Schafer W, Reinbold J, Martinez D , Garcia de Albeniz X , Gini R, Ryan O, Young J. Target trial emulation with real world evidence: regulatory grade pharmacoepidemiology in the SIGMA consortium . Presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Pajouheshnia R , Gini R, Gutierrez L , Swertz MA, Hyde E, Sturkenboom M, Arana A , Franzoni C , Ehrenstein V, Roberto G, Gil M, Macia MA, Schafer W, Haug U, Thurin NH, Lassalle R, Droz-Perroteau C, Zaccagnino S, Busto MP, Middelkoop B, Gembert K, Sanchez-Saez F, Rodriguez-Bernal C, Sanfelix-Gimeno G, Hurtado I, Acosta MB, Poblador-Plou B, Carmona-Pirez J, Gimeno-Miguel A, Prados-Torres A, Schultze A, Jansen E, Herings R, Kuiper J, Locatelli I, Jazbar J, Zerovnik S, Kos M, Smit S, Lind S, Metspalu A, Simou S, Hedenmalm K, Cochino A, Alcini P, Kurz X, Perez-Gutthann S . Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies (MINERVA): development and pilot of a metadata list and catalogue in Europe . Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5871. doi: 10.1002/pds.5871
Herring WL , Gallagher ME, Shah N, Morse KC, Mladsi D , Dong OM , Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States . Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9
Gini R, Pajouheshnia R , Gardarsdottir H, Bennett D, Li L, Gulea C, Wientzek-Fleischmann A, Bazelier MT, Burcu M, Dodd C, Duran CE, Kaplan S, Lanes S, Marinier K, Roberto G, Soman K, Zhou X, Platt R, Setoguchi S, Hall GC. Describing diversity of real world data sources in pharmacoepidemiologic studies: the DIVERSE scoping review . Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5787. doi: 10.1002/pds.5787
Tam S, Neslund-Dudas C, Barrett AM , Barrow LCJ, Fridman I, Kinlaw AC, Puviindran P, Royce TJ, Smith AB, Stein JN, Wood WA, Lafata JE. The perceived usability of virtual visits among black adults' receiving oncology care: a qualitative analysis . Oncologist. 2024 Feb 2;29(2):e237-47. doi: 10.1093/oncolo/oyad260
Romijnders R, Salis F, Hansen C, Kuderle A, Paraschiv-Ionescu A, Cereatti A, Alcock L, Aminian K, Becker C, Bertuletti S, Bonci T, Brown P, Buckley E, Cantu A, Carsin AE , Caruso M, Caulfield B, Chiari L, D'Ascanio I, Del Din S, Eskofier B, Fernstad SJ, Frohlich MS, Garcia Aymerich J, Gazit E, Hausdorff JM, Hiden H, Hume E, Keogh A, Kirk C, Kluge F, Koch S, Mazza C, Megaritis D, Mico-Amigo E, Muller A, Palmerini L, Rochester L, Schwickert L, Scott K, Sharrack B, Singleton D, Soltani A, Ullrich M, Vereijken B, Vogiatzis I, Yarnall A, Schmidt G, Maetzler W. Ecological validity of a deep learning algorithm to detect gait events from real-life walking bouts in mobility-limiting diseases . Front Nuerol. 2023 Oct 16;14:1247532. doi: 10.3389/fneur.2023.1247532
Kawai A , Fuller CC, Koram N, Agan A, Brown J, Burk J, Cai B, Daniels K, Fearrington J, Franklin JM, Hague C, Jamal-Allial A, Johannes CB , Kempner M, Layton JB , Ma Q, Mai X, Mayer SE, Pawloski PA, Reynolds JS, Seals RM, Selvan M, Smith S, McMahill-Walraven CN, Gilsenan A , Platt R. Monitoring results from a postapproval safety study of Pfizer-BioNTech COVID-19 vaccine in the United States: vaccine utilization and incidence rates of myocarditis/pericarditis . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):182. doi: 10.1002/pds.5687
Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Douglas SRG, Rizzo RRN, Devonshire JJ, Williams SA, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X , Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review . JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023
Carrico J, Mellott CE, Talbird SE , Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program . Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Johannes CB , Beachler DC, Layton JB , Danysh HE , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE , Johannes CB , Beachler DC, Layton JB , Ziemiecki R , Arana A , Dinh J, Li L, Calingaert B , Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A . Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting . Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Wang SV, Pottegard A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-Gutthann S , Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR task force . Pharmacoepidemiol Drug Saf. 2023 Jan;32(1):44-55. doi: 10.1002/pds.5507